Qube Research & Technologies LTD Mersana Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

$62.3 Billion
Q2 2024

A detailed history of Qube Research & Technologies LTD transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 992,565 shares of MRSN stock, worth $2.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

992,565

Previous 959,695 3.43%

Holding current value

$2.55 Million

Previous $4.3 Million 53.59%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.0 - $4.45 $65,740 - $146,271	32,870 Added 3.43%	992,565 $2 Million
Q1 2024 May 14, 2024	BUY	$2.16 - $5.94 $2.07 Million - $5.7 Million	959,695 New	959,695 $4.3 Million
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $146,885 - $455,439	-47,690 Reduced 18.94%	204,106 $671,000
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $661,640 - $1.16 Million	165,410 Added 191.48%	251,796 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $176,828 - $245,994	31,297 Added 56.81%	86,386 $506,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $147,988 - $255,704	31,963 Added 138.21%	55,089 $372,000
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $784,771 - $1.38 Million	-276,328 Reduced 92.28%	23,126 $107,000
Q1 2022 May 09, 2022	BUY	$3.74 - $6.63 $903,946 - $1.6 Million	241,697 Added 418.47%	299,454 $1.2 Million
Q4 2021 Feb 01, 2022	BUY	$5.48 - $9.86 $316,508 - $569,484	57,757 New	57,757 $359,000
Q3 2021 Nov 12, 2021	SELL	$8.56 - $14.47 $536,583 - $907,051	-62,685 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$13.28 - $18.07 $832,456 - $1.13 Million	62,685 New	62,685 $851,000

Others Institutions Holding MRSN

# of Institutions

124

Shares Held

115M

Call Options Held

73.5K

Put Options Held

46.4K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $250M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Mersana Therapeutics, Inc. Transaction History